Table 4.
Risk factors for virologic breakthrough by univariable and multivariable analysesa
| Risk factor for VB | Univariable analysis |
Multivariable analysis |
||
|---|---|---|---|---|
| Unadjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
| Gender | ||||
| Female | 1.00 | |||
| Male | 3.04 (0.93–9.96) | 0.066 | ||
| Age, yr | ||||
| <50 | 1.00 | |||
| ≥50 | 0.93 (0.33–2.64) | 0.890 | ||
| HBeAg | ||||
| Negative | 1.00 | |||
| Positive | 3.06 (1.10–8.47) | 0.031 | ||
| HBV DNA titer, IU/ml | ||||
| <2,000 | 1.00 | 1.00 | ||
| ≥2,000 | 9.62 (2.01–45.9) | 0.005 | 9.94 (1.91–51.6) | 0.0063 |
| Liver cirrhosis | ||||
| No | 1.00 | |||
| Yes | 1.14 (0.37–3.53) | 0.830 | ||
| Type of malignancy | ||||
| Oncologic | 1.00 | |||
| Hematologic | 2.39 (0.85–6.70) | 0.098 | ||
| Use of steroid | ||||
| No | 1.00 | |||
| Yes | 1.00 (0.30–3.37) | 1.000 | ||
| Use of anthracycline | ||||
| No | 1.00 | |||
| Yes | 1.91 (0.70–5.23) | 0.210 | ||
| Use of rituximab | ||||
| No | 1.00 | 1.00 | ||
| Yes | 3.28 (1.01–10.7) | 0.048 | 3.19 (1.14–8.96) | 0.027 |
| Primary liver cancerb | ||||
| No | 1.00 | |||
| Yes | 0.74 (0.10–5.25) | 0.760 | ||
| Distant metastasis | ||||
| No | 1.00 | |||
| Yes | 0.82 (0.26–2.59) | 0.730 | ||
a
CI, confidence interval; HR, hazard ratio; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; VB; virologic breakthrough.
b
Primary liver cancer includes either hepatocellular carcinoma or cholangiocarcinoma but not metastatic liver cancer.